CClinicalTrials.gg
CompletedNCT04802681Updated Jul 17, 2023

Pressure Guidewire Comparison

A Phase 4 interventional study of FFR-measurement with different pressure guidewires in Coronary Artery Disease and Myocardial Ischemia, sponsored by Lokien van Nunen. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Lokien van Nunen · Phase 4, Interventional, and Diagnostic

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Fractional flow reserve (FFR) is the current gold standard for correct decision making with respect to revascularization in the catheterization laboratory. FFR is measured by using a pressure guidewire equipped with a pressure sensor, positioned distal to the stenosis under investigation. A newly developed pressure wire using open wire technology has recently become commercially available. The purpose of this study is to evaluate whether the Wirecath pressure guidewire can be used as standard pressure guidewire.

The effectiveness of the device will be investigated by comparing Wirecath FFR measurements with the measurements of another regular sensor-tipped pressure guidewires during simultaneous FFR measurements in the same vessel.

Read the detailed description

FFR is a lesion-specific pressure-derived index of functional severity, defined as the maximum myocardial blood flow in the presence of an epicardial stenosis compared with the maximum flow in the hypothetical absence of the stenosis. FFR is measured by advancing a pressure guidewire into the coronary artery distal to the lesion under investigation and maintained in that position. Distal coronary pressure (Pd) and aortic pressure (Pa) are measured simultaneously while inducing steady state maximum hyperemia. FFR is defined as the lowest value of Pd/Pa achieved during maximum hyperemia. An FFR value = or \< 0.80 indicates the presence of myocardial ischemia and indicates PCI is warranted.

Existing 0.014" wires with pressure measurement capabilities have been available for more than 20 years. Improvements have been done over time, but they are still regarded as inferior to ordinary guidewires when it comes to maneuverability and general guidewire properties. This is attributed to the microelectronics that are needed to facilitate the pressure measurements in these wires. These existing wires also have issues with signal stability which is often referred to as 'drift'. Drift is an electronical phenomenon that leads to a slow progressive change in the pressure value over time. a not entirely reliable signal quality.

A relatively new pressure guidewire, Wirecath, is an equivalent device to the currently commercially available pressure guidewires. In comparative bench tests it has shown very good maneuverability. Moreover due to the 'open wire' technology (and thus lack of microelectronics throughout the wire), the Wirecath has very stable signal properties and is, according to physical law and bench testing, immune against a hydrostatic error and less affected by drifting of the signal, which are limitations with current pressure guidewires.

This study is designed to examine and compare the pressure measurements of two commercially available pressure guidewires (Abbott and Cavis Technologies) by simultaneously measuring FFR in the same coronary artery with two different pressure guidewires.

02

Conditions studied

  • Coronary Artery Disease
  • Myocardial Ischemia

Keywords

  • Fractional Flow Reserve
  • Pressure wire
  • Drift
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's enrollment of 50 is below the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Lokien van Nunen is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-80 years
  • Scheduled to undergo invasive FFR measurement
  • Coronary artery lesions located in the proximal or mid part of the coronary artery
  • Reference diameter of at least 2.0mm

Exclusion criteria

Exclusion Criteria:

  • Severe aortic valve stenosis
  • known conduction disturbances (second- or third-degree AV block)
  • acute myocardial infarction (CK >1,000 U/L less than 5 days ago)
  • bradycardia (less than 45 beats/min)
  • severe hypotension
  • extremely tortuous or calcified coronary arteries precluding FFR measurement
  • history of severe asthma
  • pregnancy
  • inability to provide informed consent.
05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Other
    Wirecath - PressureWire X

    Patients will undergo simultaneous FFR measurements with the Wirecath and PressureWire X simultaneously.

    Device: FFR-measurement with different pressure guidewires

Interventions

  • DeviceFFR-measurement with different pressure guidewires

    Measuring FFR with different pressure guidewires

06

What researchers measure

Primary outcomes

  1. FFR

    To compare the pressure signals measured by the different available pressure guidewires, specifically the FFR value

    Time frame: During catheterization

  2. Hydrostatic error

    To assess the occurrence of hydrostatic errors when using sensor-tipped wires

    Time frame: During catheterization

  3. Drift

    To assess the occurrence of drift between the different pressure guidewires

    Time frame: During catheterization

Secondary outcomes

  1. Signal quality

    To assess signal quality and stability between the different pressure guidewires

    Time frame: During catheterization

  2. Maneuverability

    To assess maneuverability and handling of the different pressure guidewires

    Time frame: During catheterization

07

Study locations

1 site
  • Catharina Hospital
    Eindhoven, Noord-Brabant 5623EJ, Netherlands
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual (non-anonymized) participant data available to others.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04802681
Lead sponsor
Lokien van Nunen
Collaborators
Cavis Technologies AB
Responsible party
Lokien van Nunen (Fellow Interventional Cardiology, Catharina Ziekenhuis Eindhoven) — Sponsor-investigator
First posted
Mar 17, 2021
Start date
Dec 1, 2021
Primary completion
Jan 19, 2023
Completion
Jan 19, 2023
Last update
Jul 17, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion